Researchers have shown that dopamine-producing cells grown in a laboratory can remain alive and work in the human brain after being transplanted to treat Parkinson’s disease.
The finding recasts a long-pursued ambition: restoring movement by replacing the brain cells that have been lost, instead of merely controlling symptoms.
Inside the trial
In a controlled clinical trial in Japan, the transplanted cells continued to exist in a brain region crucial to movement and closely linked with Parkinson’s symptoms.
Kyoto University surgeons and neurologists recorded that the implanted cells stayed active and generated dopamine throughout a 24-month period.
Several patients showed measurable gains in motor function, particularly during periods when their usual medication was not taking effect.
These findings provide an early indication of clinical feasibility, although questions remain about reliable results and lasting effectiveness.
Why movement suffers
More than 8.5 million people around the world live with Parkinson’s disease, with movement difficulties often worsening as the brain’s chemical systems deteriorate.
The condition harms the brain cells responsible for producing dopamine, a chemical messenger that helps movements remain controlled and fluid.
When these cells die, movement signals from the brain become weaker, leading to tremor, rigidity, slower walking and problems with balance across the body.
This declining system helps explain why researchers have long been drawn to replacing cells rather than simply supplying more medicine.
How raguneprocel cells are made
Called raguneprocel, the treatment starts with donated adult blood cells from a healthy donor, not embryonic cells.
Scientists reprogramme these cells into induced pluripotent stem cells, bringing them back to a flexible state.
Researchers then guide the flexible cells in the laboratory to become immature dopamine-producing brain cells intended for transplantation.
Thorough sorting removes unwanted cell types, reducing a risk that affected earlier approaches using mixed cell sources.
Targeting brain regions
Surgeons implanted clusters of cells in the putamen, a deep movement-control region on each side of the brain.
Using three routes on each side enabled clinicians to distribute the dose instead of placing it in a single concentrated location.
Participants were also given an immunosuppressant, a drug used to reduce the chance of rejection because donor cells may prompt an immune response.
The later withdrawal of that drug without visible inflammation offered a more reassuring safety signal for participants, though it was not definitive.
Signs of clinical benefit
At the two-year point, four of six assessed patients had improved movement during periods when their standard Parkinson’s medication had worn off.
Five improved while their medication was working, suggesting the grafts may provide additional support rather than fully replacing tablets.
Brain scans found a 44.7% increase in dopamine-producing activity in the putamen after transplantation, with the strongest rise seen in people receiving higher doses.
Other measures of daily living changed to a lesser extent, making movement assessments and brain chemistry the most distinct signals.
Safety concerns remain
Safety was especially important because transplanted cells may grow, spread or cause harm inside the living brain following surgery.
Clinicians reported no serious adverse events, while scans found no tumour-like overgrowth over the 24-month follow-up.
Six of seven patients experienced increased dyskinesia, the involuntary movements that can occur after dopamine treatment, mainly when medication was active.
This differed from the feared graft-related movements, which commonly arise during off periods when medication is not working.
Regulation and oversight
Japan’s approval can remain in place for up to seven years under a conditional scheme, allowing evidence to accumulate while patients gain monitored access.
Through this regulatory route, which permits supervised early access, companies are required to gather real-world information on safety and benefit.
In Japan, eligible patients must have movement symptoms that standard drug treatment no longer controls sufficiently.
The limited conditional approval of raguneprocel represented an important scientific milestone for the Parkinson’s community.
It follows decades of regenerative-medicine research and provides early evidence that cell-based therapies may eventually form part of treatment.
Why earlier trials failed
Previous cell-replacement programmes used fetal tissue, and some recipients improved for years after those grafts survived in the brain.
However, later large blinded trials disappointed clinicians, in part because outcomes differed between patients and some recipients developed side effects despite careful surgery.
Difficulties with donor supply and ethical concerns also made fetal tissue unsuitable as a dependable source for routine treatment.
Reprogrammed donor cells provided a more standardised source, although Japan’s trial still revealed that responses varied from one person to another.
What remains unknown
A trial involving seven people cannot establish whether the treatment will work across large groups with different forms or earlier stages of the disease.
As this was an open-label study, in which all participants knew they had received treatment, expectations may have affected certain movement scores.
Larger studies with comparison groups are still needed to distinguish a genuine cell effect from placebo effects and observer bias.
Extended follow-up must also determine whether the transplanted cells continue to function for many years without delayed inflammation or tumour growth.
Future of cell therapy
The survival of the grafts, cautious approval and measurable dopamine activity bring this treatment from aspiration into supervised clinical use.
Future controlled trials will need to establish who benefits, the number of cells that should be implanted and the duration of any improvements.
Comments
No comments yet. Be the first to comment!
Leave a Comment